Insights Into Acute Myeloid Leukemia (AML)

Perspectives of community physicians on the treatment of acute myeloid leukemia (AML) , recently introduced and upcoming agents

Central April 15, 2021

Faculty Chair

Gabriel Mannis, MD

Stanford Health Care, Stanford, CA

Southeast September 14, 2021

Faculty Chair

TBC

More information

  • Virtual Series
  • Arkansas, Kansas, Louisiana, Missouri, Oklahoma, Texas

More Information

  • Virtual Series
  • Alabama, Florida, Georgia, Kentucky, Mississippi, North Carolina, South Carolina, Tennessee, Virginia, West Virginia

Example Agenda

Export meeting topics

View Agenda

Example Report

Start discovering the insights

View Report

REPORT SNAPSHOT

  • A virtual, moderated roundtable discussion focusing on the treatment of acute myeloid leukemia
  • Disease state and data presentations are developed in conjunction with a national or regional oncology expert
  • Insights on the following AML therapies were obtained: venetoclax, gilteritinib, CC-486, azacitidine, cytarabine and daunorubicin (ie, 7+3), CPX-351, ivosidenib, gemtuzumab ozogamicin, midostaurin, and sorafenib

GEOGRAPHIC REPRESENTATION & CONTENT DEVELOPMENT

  • Data collection is accomplished through use of audience response system questioning and moderated discussion
  • The group of advisors will comprise 10–15 medical oncologists representative of each region

Purchase Report

Thank you for your interest in our insights.

Complete the form below to receive additional information.